CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 646,508	$ 809,102
Marketable securities	398,656	236,121
Accounts receivable - trade, net	1,431,966	1,152,489
Accounts Receivable from Sanofi	138,067	153,152
Accounts receivable from Bayer	181,938	162,152
Inventories	316,073	238,578
Prepaid expenses and other current assets	96,017	163,501
Total current assets	3,209,225	2,915,095
Marketable securities	589,852	632,162
Property, plant, and equipment, net	1,772,923	1,594,120
Deferred tax assets	626,191	461,945
Other assets	6,715	5,810
Total assets	6,204,906	5,609,132
Current liabilities:
Accounts payable and accrued expenses	759,643	644,112
Deferred revenue from Sanofi, current portion	104,141	101,573
Deferred revenue - other, current portion	84,084	51,914
Other current liabilities	3,695	13,563
Total current liabilities	951,563	811,162
Deferred revenue from Sanofi	549,342	582,664
Deferred Revenue - other	146,449	82,015
Facility lease obligations	361,523	362,919
Other long-term liabilities	119,523	115,535
Total liabilities	2,128,400	1,954,295
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,156,942	3,099,526
Retained earnings	1,230,303	852,700
Accumulated other comprehensive income	5,204	8,572
Treasury stock	(316,052)	(306,069)
Total stockholders' equity	4,076,506	3,654,837
Total liabilities and stockholders' equity	6,204,906	5,609,132
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 107	$ 106